Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Terminated Not applicable Interventional

Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders

NCT00508560
View directory record Official record
Conditions
Nicotine Dependence, Psychotic Disorders
Interventions
Contingency Management, Reward
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 26, 2026, 5:12 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of V132 in Healthy Older Participants (V132-001)

NCT07712575
View directory record Official record
Conditions
Healthy
Interventions
V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q, Fluzone Quadrivalent
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 26, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

NCT02839915
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Folinic Acid, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
5 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Lexington, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

NCT03086460
View directory record Official record
Conditions
Asthma
Interventions
CHF 1531 pMDI, Formoterol Inhalation Solution, Placebo pMDI
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

BPL-003 Efficacy and Safety in Treatment Resistant Depression

NCT05870540
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
BPL-003
Drug
Lead sponsor
Beckley Psytech Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2)
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Months to 15 Months
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
15
States / cities
Madera, California • Miami, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Patient-Centered Physical Activity Program for Hemodialysis Patients

NCT07080593
View directory record Official record
Conditions
Hemodialysis
Interventions
Novel Physical Activity Program, Standard of Care Physical Activity Program
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Bolingbrook, Illinois • Oak Brook, Illinois • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Automatic Thermomechanical Massage Bed for Acute Pain Relief for Chronic Nonspecific Low Back Pain

NCT06769321
View directory record Official record
Conditions
Chronic Non-specific Low Back Pain
Interventions
Automatic Thermo-mechanical Massage Bed
Device
Lead sponsor
The City College of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)

NCT07732699
View directory record Official record
Conditions
ACUTE SINUSITIS, Sinusitis
Interventions
Amoxicillin, Amoxi Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Years to 12 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety

NCT03837392
View directory record Official record
Conditions
Post Partum Depression, Perinatal Depression, Post Partum Anxiety, Perinatal Anxiety
Interventions
Baseline Assessment (18-26 weeks pregnant), Online Intervention and Phone Coaching Interventions, Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum, Follow Up Assessments: 8 weeks postpartum
Diagnostic Test · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Simplified Onboarding in Adults With Type 2 Diabetes

NCT07070830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Active Comparator: Omnipod M System with lower starting dose, Active Comparator: Omnipod M System with higher starting dose
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.

NCT01762475
View directory record Official record
Conditions
Traumatic Brain Injury, Post-concussive Syndrome
Interventions
Sildenafil
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474
View directory record Official record
Conditions
Wounds
Interventions
Placebo gel, GLYC-101 gel (1.0 %)
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Citicoline for Alcohol Dependence

NCT02074735
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Placebo, Citicoline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 26, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

NCT02744755
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab - GP2017, Adalimumab - US licensed Humira
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Mesa, Arizona • Peoria, Arizona • Covina, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 26, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

NCT02091986
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, Budesonide pMDI
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
59
States / cities
Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 26, 2026, 5:12 AM EDT